Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Orchestra BioMed Holdings (OBIO)
NASDAQ:OBIO
RESEARCH TOOLSreports
Orchestra BioMed Holdings (OBIO) Stock Price & Analysis
48 Followers
OBIO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.26 - $20.19
Previous Close$4.71
Volume30.36K
Average Volume (3M)50.16K
Market Cap
$168.51M
Enterprise Value$82.60M
Total Cash (Recent Filing)$87.59M
Total Debt (Recent Filing)$1.69M
Price to Earnings (P/E)-3.2
Beta0.24
Next Earnings
May 10, 2024EPS Estimate
-$0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.48
Shares Outstanding35,743,972
10 Day Avg. Volume26,639
30 Day Avg. Volume50,157
Standard Deviation0.24
R-Squared0.00088
Alpha0.00543
Financial Highlights & Ratios
Price to Book (P/B)2.45
Price to Sales (P/S)59.83
Price to Cash Flow (P/CF)-3.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue29.93
Enterprise Value/Gross Profit29.93
Enterprise Value/Ebitda-3.29
Forecast
1Y Price Target
$17.50Price Target Upside271.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Orchestra BioMed Holdings News
Bulls Say, Bears Say
Bulls Say
Product PipelineBackBeat CNT is designed to 'substantially' reduce blood pressure in patients with hypertension (HTN), representing a significant advancement in the treatment of this widespread condition.
Regulatory MilestonesThe FDA has approved Orchestra Biomed's IDE for a U.S. pivotal study to evaluate Virtue SAB as a treatment for patients with coronary in-stent restenosis, highlighting the product's potential to meet an unmet medical need.
Strategic PartnershipsOrchestra Biomed (OBIO) is using strategic collaborations with established companies to bring breakthrough products to market, a relatively novel approach in medtech.
Bears Say
Increased Cash BurnThe company's substantial cash burn from operations indicates a faster depletion of financial resources, which could lead to liquidity concerns.
Regulatory DelayThe delay in regulatory clearance for AVIM therapy may negatively impact investor confidence, as the US commercial launch is now postponed.
Revenue DeclineOBIO's significant drop in revenue, nearly halving year-over-year, suggests a troubling decrease in the company's financial performance.
---
Options Prices
Currently, No data available
---
Ownership Overview
56.12% Insiders
6.78% Mutual Funds
28.96% Other Institutional Investors
8.15% Public Companies and
Individual Investors
OBIO FAQ
What was Orchestra BioMed Holdings’s price range in the past 12 months?
Orchestra BioMed Holdings lowest stock price was $4.25 and its highest was $20.19 in the past 12 months.
What is Orchestra BioMed Holdings’s market cap?
Currently, no data Available
When is Orchestra BioMed Holdings’s upcoming earnings report date?
Orchestra BioMed Holdings’s upcoming earnings report date is May 10, 2024 which is in 14 days.
How were Orchestra BioMed Holdings’s earnings last quarter?
Orchestra BioMed Holdings released its earnings results on Mar 27, 2024. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.376 by $0.026.
Is Orchestra BioMed Holdings overvalued?
According to Wall Street analysts Orchestra BioMed Holdings’s price is currently Undervalued.
Does Orchestra BioMed Holdings pay dividends?
Orchestra BioMed Holdings does not currently pay dividends.
What is Orchestra BioMed Holdings’s EPS estimate?
Orchestra BioMed Holdings’s EPS estimate is -$0.4.
How many shares outstanding does Orchestra BioMed Holdings have?
Orchestra BioMed Holdings has 35,777,412 shares outstanding.
What happened to Orchestra BioMed Holdings’s price movement after its last earnings report?
Orchestra BioMed Holdings reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.376. Following the earnings report the stock price went down -0.566%.
Which hedge fund is a major shareholder of Orchestra BioMed Holdings?
Among the largest hedge funds holding Orchestra BioMed Holdings’s share is Perceptive Advisors LLC. It holds Orchestra BioMed Holdings’s shares valued at 22M.
---
Orchestra BioMed Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.50 (271.55% Upside)
$17.50 (271.55% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 19.3%
Last 30 Days ▲ 19.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-78.97%
12-Months-Change
Fundamentals
Return on Equity
-76.29%
Trailing 12-Months
Asset Growth
39.86%
Trailing 12-Months
Company Description
Orchestra BioMed Holdings
Health Sciences Acquisitions Corp 2 is a blank check company.
---
OBIO Stock 12 Months Forecast
Average Price Target
$17.50
▲(271.55% Upside)
Technical Analysis
Best Analysts Covering OBIO
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-25.97%
assigned a buy rating 29 days ago
Copying Matthew O'Brien's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -25.97% per trade.
---